Shares

17 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024

SELL
$0.92 - $1.6 $2,734 - $4,755
-2,972 Reduced 21.8%
10,660 $11,000
Q3 2023

Nov 13, 2023

BUY
$1.63 - $3.94 $22,220 - $53,710
13,632 New
13,632 $22,000
Q2 2022

Aug 15, 2022

SELL
$4.1 - $7.36 $7,199 - $12,924
-1,756 Reduced 14.6%
10,272 $42,000
Q1 2022

May 16, 2022

SELL
$6.64 - $8.21 $21,394 - $26,452
-3,222 Reduced 21.13%
12,028 $89,000
Q4 2021

Feb 14, 2022

SELL
$6.57 - $9.78 $70,299 - $104,646
-10,700 Reduced 41.23%
15,250 $113,000
Q3 2021

Nov 15, 2021

SELL
$8.85 - $12.5 $61,516 - $86,887
-6,951 Reduced 21.13%
25,950 $260,000
Q2 2021

Aug 17, 2021

SELL
$9.53 - $14.7 $20,937 - $32,295
-2,197 Reduced 6.26%
32,901 $407,000
Q1 2021

May 17, 2021

BUY
$8.75 - $15.49 $203,918 - $360,994
23,305 Added 197.62%
35,098 $435,000
Q4 2020

Feb 16, 2021

SELL
$7.11 - $9.99 $51,199 - $71,937
-7,201 Reduced 37.91%
11,793 $115,000
Q3 2020

Nov 16, 2020

BUY
$7.15 - $8.73 $23,380 - $28,547
3,270 Added 20.8%
18,994 $138,000
Q2 2020

Aug 14, 2020

SELL
$6.15 - $9.4 $397,363 - $607,352
-64,612 Reduced 80.43%
15,724 $141,000
Q1 2020

May 15, 2020

BUY
$5.88 - $15.75 $472,375 - $1.27 Million
80,336 New
80,336 $567,000
Q4 2019

Feb 14, 2020

SELL
$7.5 - $17.15 $194,842 - $445,539
-25,979 Closed
0 $0
Q3 2019

Nov 14, 2019

BUY
$7.7 - $10.48 $99,537 - $135,474
12,927 Added 99.04%
25,979 $234,000
Q2 2019

Aug 14, 2019

BUY
$6.78 - $9.49 $10,054 - $14,073
1,483 Added 12.82%
13,052 $119,000
Q1 2019

May 15, 2019

SELL
$5.71 - $7.19 $14,994 - $18,880
-2,626 Reduced 18.5%
11,569 $78,000
Q4 2018

Feb 14, 2019

BUY
$5.79 - $8.1 $82,189 - $114,979
14,195 New
14,195 $85,000

Others Institutions Holding SLGL

About Sol-Gel Technologies Ltd.


  • Ticker SLGL
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 23,129,500
  • Market Cap $12.5M
  • Description
  • Sol-Gel Technologies Ltd., a clinical stage specialty pharmaceutical company, focuses on developing and commercializing topical dermatological drug products based on its proprietary microencapsulation delivery system in Israel. The company's lead product candidates include Twyneo, a novel, once-daily, non-antibiotic topical cream which has compl...
More about SLGL
Track This Portfolio

Track Invesco Ltd. Portfolio

Follow Invesco Ltd. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Invesco Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Invesco Ltd. with notifications on news.